| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-07-25 | PEGPH20 and pembrolizumab | non-small cell lung cancer (NSCLC), gastric cancer | 1b | Halozyme Therapeutics (USA - CA) | Cancer - Oncology |
| 2016-07-25 | afatinib | metastatic and recurrent head and neck cancer | 3 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
| 2016-07-22 | human Retinal Progenitor Cell (hRPC) therapy | retinitis pigmentosa | preclinical | Reneuron (UK) | Ophtalmological diseases |
| 2016-07-21 | CA4P (fosbretabulin tromethamine) and pazopanib | ovarian cancer | 1b-2 | Mateon Therapeutics (USA - CA), Novartis (Switzerland) | Cancer - Oncology |
| 2016-07-21 | crenolanib | advanced or metastatic gastrointestinal stromal tumors (GIST) with D842V mutated PDGFRA gene | 3 | Arog Pharmaceuticals (USA -TX) | Cancer - Oncology |
| 2016-07-21 | Odefsey®(emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) | HIV-1 infection | 3b | Gilead Sciences (USA - CA) | Infectious diseases |
| 2016-07-21 | neratinib - PB272 | extended adjuvant treatment of HER2-positive early stage breast cancer | 3 | Puma Biotechnology (USA - CA) | Cancer - Oncology |
| 2016-07-21 | ABP 980 (biosimilar version of trastuzumab - Herceptin®) | breast cancer | 3 | Amgen (USA - CA) Allergan (Ireland) | Cancer - Oncology |
| 2016-07-19 | ZGN-440 (beloranib) | Prader-Willi syndrome | 3 | Zafgen (USA - MA) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2016-07-19 | ZGN-440 (beloranib) | severe obesity complicated by type 2 diabetes | 2b | Zafgen (USA - MA) | Metabolic diseases |
| 2016-07-18 | megaTAL genome editing platform | Bluebird bio (USA - MA) | |||
| 2016-07-18 | AB-PA01 - AmpliPhage-001 (Pseudomonas aeruginosa bacteriophages) | Pseudomonas aeruginosa infections | preclinical | AmpliPhi BioSciences (USA - VA) | Infectious diseases - Rare diseases |
| 2016-07-18 | Adcetris® (brentuximab vedotin) | relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) | 2 | Seattle Genetics (USA - WA) Takeda Pharmaceutical (Japan) | Cancer - Oncology |
| 2016-07-15 | ALD403 | chronic migraine | 2b | Alder Biopharmaceuticals (USA - WA) | CNS diseases - Neurological diseases |
| 2016-07-14 | RNActive® technology | Curevac (Germany) | Infectious diseases | ||
| 2016-07-14 | hypertrophic cardiomyopathy | registry study | Myokardia (USA - CA) | Cardiovascular diseases | |
| 2016-07-14 | AGS-004 and vorinostat | HIV infection | 2 | Argos Therapeutics (USA - NC) | Infectious diseases |
| 2016-07-14 | recombinant human beta-glucuronidase (rhGUS, UX003) | mucopolysaccharidosis 7 (MPS 7, Sly syndrome) | 3 | Ultragenyx Pharmaceutical (USA - CA) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2016-07-13 | BI 836845 and abemaciclib (LY2835219) | metastatic breast cancer | 2 | Boehringer Ingelheim (Germany) Eli Lilly (USA - IN) | Cancer - Oncology |
| 2016-07-12 | IMP321 | solid tumors | 1 | Prima Biomed (Australia) Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH (Germany) | Cancer - Oncology |
